GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 2seventy bio Inc (NAS:TSVT) » Definitions » Return-on-Tangible-Equity

2seventy bio (2seventy bio) Return-on-Tangible-Equity : -93.70% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is 2seventy bio Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. 2seventy bio's annualized net income for the quarter that ended in Mar. 2024 was $-210.69 Mil. 2seventy bio's average shareholder tangible equity for the quarter that ended in Mar. 2024 was $224.86 Mil. Therefore, 2seventy bio's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was -93.70%.

The historical rank and industry rank for 2seventy bio's Return-on-Tangible-Equity or its related term are showing as below:

TSVT' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -1515.24   Med: -148.43   Max: -75.41
Current: -75.41

During the past 6 years, 2seventy bio's highest Return-on-Tangible-Equity was -75.41%. The lowest was -1,515.24%. And the median was -148.43%.

TSVT's Return-on-Tangible-Equity is ranked worse than
64.25% of 1309 companies
in the Biotechnology industry
Industry Median: -47.16 vs TSVT: -75.41

2seventy bio Return-on-Tangible-Equity Historical Data

The historical data trend for 2seventy bio's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

2seventy bio Return-on-Tangible-Equity Chart

2seventy bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial -1,515.24 -311.92 -148.43 -80.81 -80.61

2seventy bio Quarterly Data
Dec18 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -55.87 -46.08 -88.42 -82.90 -93.70

Competitive Comparison of 2seventy bio's Return-on-Tangible-Equity

For the Biotechnology subindustry, 2seventy bio's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


2seventy bio's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 2seventy bio's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where 2seventy bio's Return-on-Tangible-Equity falls into.



2seventy bio Return-on-Tangible-Equity Calculation

2seventy bio's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-217.57/( (291.108+248.706 )/ 2 )
=-217.57/269.907
=-80.61 %

2seventy bio's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-210.692/( (248.706+201.022)/ 2 )
=-210.692/224.864
=-93.70 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


2seventy bio  (NAS:TSVT) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


2seventy bio Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of 2seventy bio's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


2seventy bio (2seventy bio) Business Description

Traded in Other Exchanges
N/A
Address
60 Binney Street, Cambridge, MA, USA, 02142
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
Executives
Nick Leschly director, officer: President and CEO C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Philip D Gregory officer: Chief Scientific Officer POINT RICHMOND TECH CENTER II, 501 CANAL BOULEVARD SUITE A100, RICHMOND CA 94804
Baird William D Iii officer: Chief Financial Officer C/O BLUEBIRD BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Yue Tang 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Kynam Fund Gp, Llc 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Kynam Global Healthcare Master Fund, Lp 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Kynam Capital Management Gp, Llc 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Kynam Capital Management, Lp 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Lin Wei director C/O ERASCA, INC., 10835 ROAD TO THE CURE, SUITE 140, SAN DIEGO CA 92121
Nicola Heffron officer: Chief Operating Officer 2SEVENTY BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Marcela V. Maus director 16 RICHMOND CIRCLE, LEXINGTON MA 02421
Ramy Ibrahim director C/O SURFACE ONCOLOGY, 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Sarah Js Glickman director 60 BINNEY STREET, C/O BLUEBIRD BIO, INC., CAMBRIDGE MA 02142
Daniel Lynch director
Denice Torres director 3 RABBIT RUN DRIVE, NEW HOPE PA 18938

2seventy bio (2seventy bio) Headlines

From GuruFocus

2seventy bio Announces Proposed Public Offering of Common Stock

By Business Wire Business Wire 02-28-2023